1. Home
  2. NAII vs GANX Comparison

NAII vs GANX Comparison

Compare NAII & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natural Alternatives International Inc.

NAII

Natural Alternatives International Inc.

N/A

Current Price

$2.68

Market Cap

21.6M

Sector

Health Care

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.49

Market Cap

100.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAII
GANX
Founded
1980
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
100.4M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
NAII
GANX
Price
$2.68
$2.49
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
23.5K
590.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
47.95
EPS
N/A
N/A
Revenue
$132,437,000.00
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.60
N/A
52 Week Low
$2.33
$1.41
52 Week High
$4.96
$4.34

Technical Indicators

Market Signals
Indicator
NAII
GANX
Relative Strength Index (RSI) 39.11 56.80
Support Level $2.64 $1.60
Resistance Level $3.01 $2.79
Average True Range (ATR) 0.15 0.20
MACD 0.02 0.08
Stochastic Oscillator 38.46 68.57

Price Performance

Historical Comparison
NAII
GANX

About NAII Natural Alternatives International Inc.

Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: